Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in <i>TP53</i> -mutated myeloid malignancies
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy
Risk prediction for clonal cytopenia: multicenter real-world evidence
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk <i>NPM1</i>-mutated AML
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])
Advancing drug development in myelodysplastic syndromes
Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study
Data from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Data from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts